Study: Collaboration across disciplines ensuring fairness of AI in healthcare
October 23rd 2023According to a study by a team of scientists led by Duke-NUS Medical School, pursuing fair AI for healthcare requires cross-disciplinary collaboration to translate methods into real-world benefits.
Read More
Michigan ophthalmologist files lawsuit over required age-based screening assessment for cognition
October 19th 2023According to a lawsuit filed in U.S. District Court in Detroit, a policy requires Henry Ford Health and Henry Ford Medical Group (HFMG) employees to undergo a screening assessment for cognition when they reach the age of 70, again at age 75 and each year after that.
Read More
FDA approves pilocarpine hydrochloride ophthalmic solution for treatment of presbyopia
October 18th 2023Orasis Pharmaceuticals announces approval of Qlosi, a preservative-free, low-dose eye drop for presbyopia, which consistently demonstrated efficacy, safety, and tolerability in two pivotal Phase 3 trials.
Read More
Conflict in Israel could have dire impact on ophthalmic care in country
October 16th 2023In the wake of the October 7 surprise attack by Hamas, Israel finds itself thrust into war, and ophthalmologists are working to provide the best care they can under the conditions they find themselves in.
Read More
ICTER researchers achieve potential breakthrough in the diagnosis of eye diseases
October 13th 2023Researchers at the Warsaw, Poland-based International Center for Translational Eye Research decided to change that by introducing a new imaging method derived from optical coherence tomography. This led to the creation of even more advanced spatio-temporal optical coherence tomography.
Read More
FDA grants 510(k) clearance to Altris IMS platform
October 4th 2023Altris has advanced AI models to enable vendor-neutral retina layer segmentation as well as detection and visualization of more than 70 retina conditions such as dry and aet age-related macular degeneration, geographic atrophy, diabetic retinopathy, diabetic macular edema and central retinal vein occlusion.
Read More
Novartis finalizes divestment of ‘front of eye’ ophthalmology assets
September 30th 2023According to the company, the divestment includes Xiidra, on-market treatment for dry eye disease and additional ophthalmic investigational therapies. Novartis will now move forward with a focused portfolio and prioritized therapeutic areas for future growth.
Read More